B
BiomX Inc. (PHGE)
ASE – Real Time Price. Currency in USD
0.64
-0.03 (-4.89%)
At close: May 12, 2026, 3:59 PM EDT
0.65
+0.01 (1.59%)
After-hours: May 12, 2026, 7:58 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
ASE – Real Time Price. Currency in USD
0.64
-0.03 (-4.89%)
At close: May 12, 2026, 3:59 PM EDT
0.65
+0.01 (1.59%)
After-hours: May 12, 2026, 7:58 PM EDT
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company’s phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.
| Name | Position |
|---|---|
| Dr. Carl R. Merril M.D. | Scientific Founder |
| Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
| Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
| Mr. David Rokach | CFO, Principal Financial Officer & Principal Accounting Officer |
| Mr. Michael Oster | CEO & Director |
| Ms. Marina Wolfson CPA | Secretary |
| Prof. Rotem Sorek Ph.D. | Scientific Founder |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 8-K | ea0289209-8k_biomx.htm |
| 2026-04-30 | 10-K/A | ea0288312-10ka1_biomx.htm |
| 2026-04-16 | 8-K | ea028664701-8k_biomx.htm |
| 2026-04-13 | 8-K | ea0285293-8k_biomx.htm |
| 2026-04-10 | S-8 | ea0285813-s8_biomx.htm |
| 2026-04-10 | 8-K | ea0285346-8k_biomx.htm |
| 2026-04-01 | 8-K | ea0284436-8k_biomx.htm |
| 2026-03-27 | 8-K | ea0283776-8k_biomx.htm |
| 2026-03-25 | DEF 14A | ea0283377-def14a_biomx.htm |
| 2026-03-19 | 8-K | ea0282582-8k_biomx.htm |